Barriers and facilitators to implement the redispensing of unused oral anticancer drugs in clinical care: A hybrid-effectiveness type I study

被引:0
作者
Smale, Elisabeth M. [1 ]
Verkerk, Eva W. [2 ]
Heerdink, Eibert R. [3 ,4 ,5 ]
Egberts, Toine C. G. [3 ,4 ]
van den Bemt, Bart J. F. [1 ,6 ]
Bekker, Charlotte L. [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Pharm, Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept IQ Healthcare, Nijmegen, Netherlands
[3] Univ Med Ctr Utrecht, Dept Clin Pharm, Div Lab Genet & Pharm, Utrecht, Netherlands
[4] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Fac Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands
[5] Univ Utrecht, Appl Med Ctr Utrecht, Res Grp Innovat Pharmaceut Care, Utrecht, Netherlands
[6] Sint Maartensklin, Dept Pharm, Ubbergen, Netherlands
来源
EXPLORATORY RESEARCH IN CLINICAL AND SOCIAL PHARMACY | 2024年 / 15卷
关键词
Medication waste; Medication redispensing; Oral anticancer drugs; Stakeholder engagement; Hybrid effectiveness-implementation design; Qualitative research; WASTE;
D O I
10.1016/j.rcsop.2024.100493
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Minimizing medication waste through the redispensing of oral anticancer drugs (OADs) that were unused by patients provides economic and environmental benefits, but this is not yet universally implemented in clinical care. Objective(S): To identify barriers and facilitators to the implementation of redispensing unused OADs in clinical care. Methods: A multicentre intervention study following a hybrid effectiveness-implementation type I design was conducted, consisting of semi-structured interviews with key stakeholders involved in the redispensing program: pharmacy employees, prescribing clinicians in oncology and haematology, patients who participated in redispensing and patients who declined trial participation. Questions encompassed experiences and suggestions for future implementation. The Consolidated Framework for Implementation Research (CFIR) guided data collection and categorisation of identified barriers and facilitators through thematic analysis. Results: In total, 35 interviews were conducted, identifying 15 themes encompassing barriers and facilitators, reflecting all CFIR domains. Facilitators encompassed: 1) convenient process requiring an acceptable time- investment; 2) support from project leaders and implementation champions; 3) being well-motivated by personal values and societal impact; 4) feeling ensured of medication quality upon redispensing; 5) endorsement by healthcare providers for patient participation; 6) clear and personal patient communication; 7) good visibility of intervention successes; and 8) implementation well supported through a collaborative network. Barriers encompassed: 1) unclear target population; 2) redispensing legally prohibited; 3) absence of financial compensation for pharmacies; 4) complexity arising from two parallel work processes; 5) widespread communication on adjustments within local teams challenging; 6) patient's low receptiveness due to burden of oncology treatment; and 7) lack of familiarization among pharmacy technicians. Conclusions: Facilitators for implementation of redispensing un used drugs mainly related to people's values, motivation, and societal demand, whereas barriers mainly encompassed practical issues, including knowledge, time, financial resources, and legal conditions. Strategies emphasizing the benefits of redispensing and further streamlining process compatibility could support implementation.
引用
收藏
页数:8
相关论文
共 44 条
[31]   The Dutch chain approach on pharmaceuticals in water: Stakeholders acting together to reduce the environmental impact of pharmaceuticals [J].
Moermond, Caroline T. A. ;
de Rooy, Marc .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (12) :5074-5082
[32]  
OECD, 2022, Management of Pharmaceutical Household Waste:Limiting Environmental Impacts of Unused or Expired Medicine
[33]   A refined compilation of implementation strategies: results from the Expert Recommendations for Implementing Change (ERIC) project [J].
Powell, Byron J. ;
Waltz, Thomas J. ;
Chinman, Matthew J. ;
Damschroder, Laura J. ;
Smith, Jeffrey L. ;
Matthieu, Monica M. ;
Proctor, Enola K. ;
Kirchner, JoAnn E. .
IMPLEMENTATION SCIENCE, 2015, 10
[34]   'Climate change mitigation is a hot topic, but not when it comes to hospitals': a qualitative study on hospital stakeholders' perception and sense of responsibility for greenhouse gas emissions [J].
Quitmann, Claudia ;
Sauerborn, Rainer ;
Danquah, Ina ;
Herrmann, Alina .
JOURNAL OF MEDICAL ETHICS, 2023, 49 (03) :204-210
[35]   A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance [J].
Skivington, Kathryn ;
Matthews, Lynsay ;
Simpson, Sharon Anne ;
Craig, Peter ;
Baird, Janis ;
Blazeby, Jane M. ;
Boyd, Kathleen Anne ;
Craig, Neil ;
French, David P. ;
McIntosh, Emma ;
Petticrew, Mark ;
Rycroft-Malone, Jo ;
White, Martin ;
Moore, Laurence .
BMJ-BRITISH MEDICAL JOURNAL, 2021, 374
[36]   Key factors underlying the willingness of patients with cancer to participate in medication redispensing [J].
Smale, E. M. ;
Egberts, T. C. G. ;
Heerdink, E. R. ;
van den Bemt, B. J. F. ;
Bekker, C. L. .
RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2022, 18 (08) :3329-3337
[37]   Cost Savings and Waste Reduction Through Redispensing Unused Oral Anticancer Drugs The ROAD Study [J].
Smale, Elisabeth M. ;
van den Bemt, Bart J. F. ;
Heerdink, Eibert R. ;
Desar, Ingrid M. E. ;
Egberts, Toine C. G. ;
Bekker, Charlotte L. .
JAMA ONCOLOGY, 2024, 10 (01) :87-94
[38]   Waste-minimising measures to achieve sustainable supply and use of medication [J].
Smale, Elisabeth M. ;
Egberts, Toine C. G. ;
Heerdink, Eibert R. ;
van den Bemt, Bart J. F. ;
Bekker, Charlotte L. .
SUSTAINABLE CHEMISTRY AND PHARMACY, 2021, 20
[39]   How to engage healthcare providers in preventing medication waste through individualized prescribing and dispensing: A qualitative study [J].
Smale, Elisabeth Marissa ;
van der Werff, Isa Belle ;
van den Bemt, Bart Johannes Fredericus ;
Bekker, Charlotte Linde .
RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2023, 19 (10) :1365-1371
[40]  
Smale EM, 2023, Radboudume